ZZPZH(SH:600436)2022-10-21 16:00Financial Performance - The company's revenue for Q3 2022 was CNY 2,193,137,955.89, representing a decrease of 3.08% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2022 was CNY 738,125,096.32, down 17.64% year-on-year[2] - The basic earnings per share for Q3 2022 was CNY 1.22, reflecting an 18.12% decrease compared to the same period last year[2] - Total operating revenue for the first three quarters of 2022 reached RMB 6,615,770,012.53, an increase of 8.25% compared to RMB 6,111,647,624.71 in the same period of 2021[14] - Operating profit for the first three quarters of 2022 was RMB 2,486,666,408.09, slightly up from RMB 2,435,842,326.43 in the previous year, reflecting a growth of 2.09%[14] - The total profit for Q3 2022 was approximately ¥2.49 billion, compared to ¥2.43 billion in Q3 2021, reflecting an increase of about 2.2%[15] - The net profit for Q3 2022 was approximately ¥2.09 billion, up from ¥2.06 billion in Q3 2021, indicating a growth of around 0.5%[15] - The basic and diluted earnings per share for Q3 2022 were both ¥3.40, compared to ¥3.33 in Q3 2021, representing an increase of 2.1%[16] - The net profit for the first three quarters of 2022 reached ¥2,028,350,590.65, representing an increase of 3.9% from ¥1,952,585,508.90 in the previous year[24] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to CNY 13,513,815,049.25, an increase of 8.15% from the end of the previous year[2] - Total assets as of September 30, 2022, amounted to RMB 13,513,815,049.25, an increase from RMB 12,495,334,742.42 at the end of 2021, representing a growth of 8.16%[12] - Current assets totaled RMB 11,706,478,022.66 as of September 30, 2022, compared to RMB 10,633,421,321.56 at the end of 2021, marking an increase of 10.08%[11] - Total liabilities decreased to RMB 2,133,733,212.87 from RMB 2,358,585,534.93, a reduction of 9.52%[11] - The total liabilities decreased to ¥417,633,917.36 from ¥748,017,862.54, reflecting improved financial health[22] Shareholder Information - Shareholders' equity attributable to the parent company reached CNY 10,897,367,492.25, up 12.29% year-on-year[2] - The company had a total of 120,113 common shareholders at the end of the reporting period[5] - The largest shareholder, Zhangzhou Jiulongjiang Group Co., Ltd., held 51.30% of the shares, totaling 309,522,643 shares[5] - The company reported a total equity of ¥8,045,721,713.68, compared to ¥6,747,384,947.13 in the previous year, indicating growth in shareholder value[22] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was CNY 6,170,796,213.66, showing a significant increase of 858.37% year-on-year[2] - Cash flow from operating activities for the first nine months of 2022 was approximately ¥6.17 billion, a significant increase from ¥643.88 million in the same period of 2021[18] - The company reported a net cash outflow from investing activities of approximately ¥5.54 billion for the first nine months of 2022, compared to a net inflow of ¥82.04 million in the same period of 2021[18] - The company incurred a net cash outflow from investing activities of ¥5,345,460,200.81, contrasting with a net inflow of ¥149,064,194.63 in the previous year[25] - The cash inflow from financing activities for Q3 2022 was approximately ¥1.20 billion, compared to ¥856.83 million in Q3 2021, showing an increase of about 40%[19] Research and Development - Research and development expenses increased to RMB 143,261,715.23 in the first three quarters of 2022, up from RMB 98,249,009.06 in the same period of 2021, indicating a growth of 45.8%[14] - Research and development expenses increased significantly to ¥123,899,232.47, up from ¥82,670,109.68, indicating a focus on innovation[23] Cash and Liquidity - The company's cash and cash equivalents decreased to RMB 2,416,361,509.10 from RMB 7,096,831,080.99, a decline of 65.96%[10] - The total cash and cash equivalents at the end of Q3 2022 were approximately ¥2.33 billion, down from ¥2.56 billion at the end of Q3 2021, showing a decrease of about 8.8%[19] - The cash and cash equivalents at the end of the period were ¥1,276,342,187.92, down from ¥1,544,456,299.94, showing a decrease in liquidity[26] - The company experienced a foreign exchange impact of ¥8,581,738.64 on cash and cash equivalents, compared to a negative impact of ¥2,016,348.18 in the previous year[26] Inventory Management - Inventory as of September 30, 2022, was RMB 2,348,551,450.20, slightly down from RMB 2,437,503,379.48 at the end of 2021, a decrease of 3.67%[10] - The company’s inventory as of September 30, 2022, was approximately ¥1.51 billion, a decrease from ¥1.69 billion at the end of 2021, reflecting a reduction of about 10.7%[21] Dividends and Payouts - The company paid out ¥730,013,824.10 in dividends and interest, an increase from ¥542,985,489.00 in the same period last year[26]